RU2014134720A - Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения - Google Patents

Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения Download PDF

Info

Publication number
RU2014134720A
RU2014134720A RU2014134720A RU2014134720A RU2014134720A RU 2014134720 A RU2014134720 A RU 2014134720A RU 2014134720 A RU2014134720 A RU 2014134720A RU 2014134720 A RU2014134720 A RU 2014134720A RU 2014134720 A RU2014134720 A RU 2014134720A
Authority
RU
Russia
Prior art keywords
hetre
paragraphs
pharmaceutical composition
microbial infection
subject
Prior art date
Application number
RU2014134720A
Other languages
English (en)
Russian (ru)
Inventor
Джонатан РОУ
Дэвид КОГЛЭН
Мехар МАНКУ
Original Assignee
Дигнити Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дигнити Сайенсиз Лимитед filed Critical Дигнити Сайенсиз Лимитед
Publication of RU2014134720A publication Critical patent/RU2014134720A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014134720A 2012-01-26 2013-01-25 Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения RU2014134720A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261591036P 2012-01-26 2012-01-26
US61/591,036 2012-01-26
US13/478,990 US20120264705A1 (en) 2012-01-26 2012-05-23 Antimicrobial compositions comprising 15-hetre and methods of use thereof
US13/478,990 2012-05-23
PCT/US2013/023201 WO2013112876A1 (en) 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Publications (1)

Publication Number Publication Date
RU2014134720A true RU2014134720A (ru) 2016-03-20

Family

ID=47006834

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014134720A RU2014134720A (ru) 2012-01-26 2013-01-25 Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения

Country Status (16)

Country Link
US (2) US20120264705A1 (cg-RX-API-DMAC7.html)
EP (1) EP2806868A4 (cg-RX-API-DMAC7.html)
JP (3) JP6557009B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140117379A (cg-RX-API-DMAC7.html)
CN (1) CN104114166A (cg-RX-API-DMAC7.html)
AU (1) AU2013211982A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018421A8 (cg-RX-API-DMAC7.html)
CA (1) CA2857046A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198921A1 (cg-RX-API-DMAC7.html)
IL (1) IL232777A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014006947A (cg-RX-API-DMAC7.html)
PH (1) PH12014501693A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014134720A (cg-RX-API-DMAC7.html)
SG (1) SG11201404088TA (cg-RX-API-DMAC7.html)
WO (1) WO2013112876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403948B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US9855236B2 (en) 2011-10-19 2018-01-02 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) * 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
GB201307082D0 (en) * 2013-04-19 2013-05-29 Dignity Sciences Ltd Pharmaceutical composition comprising 15-HETrE and methods of using the same
WO2015042442A1 (en) * 2013-09-19 2015-03-26 Dignity Sciences Limited Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
ES2727387T3 (es) * 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
LT6177B (lt) 2014-10-10 2015-07-27 Uab "Biocentras" Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN107405324A (zh) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 包含15‑hepe的组合物和其使用方法
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en) * 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US20200206173A1 (en) 2017-08-30 2020-07-02 Conopco, Inc., D/B/A Unilever A personal care composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344930A (en) * 1975-10-30 1982-08-17 Colgate-Palmolive Company Skin care sponge
JP4926310B2 (ja) * 1996-02-15 2012-05-09 エルテーベー4・スウェーデン・アクチェボラーグ 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンb4またはその類似体の使用
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US6190645B1 (en) * 1999-07-15 2001-02-20 Playtex Products, Inc. Sunscreen for the scalp hair and hair
US20030073930A1 (en) * 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) * 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
JP2009522303A (ja) * 2005-12-30 2009-06-11 ウェイ−ウー ヒー, 瘢痕を生じない皮膚創傷治癒を促進するsiRNA組成物および創傷処置の方法
JP2010509930A (ja) * 2006-11-23 2010-04-02 カーギル インコーポレイテッド 化工でんぷんの天然相当物
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
EP2159732A1 (en) * 2008-08-21 2010-03-03 Thomson Licensing Method and device for code obfuscation
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8637298B2 (en) * 2009-06-16 2014-01-28 E I Du Pont De Nemours And Company Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof

Also Published As

Publication number Publication date
US20120264705A1 (en) 2012-10-18
US20140171358A1 (en) 2014-06-19
ZA201403948B (en) 2015-12-23
AU2013211982A1 (en) 2014-06-19
BR112014018421A2 (cg-RX-API-DMAC7.html) 2017-06-20
CN104114166A (zh) 2014-10-22
MX2014006947A (es) 2015-03-05
JP6557009B2 (ja) 2019-08-07
EP2806868A4 (en) 2015-08-26
WO2013112876A1 (en) 2013-08-01
BR112014018421A8 (pt) 2017-07-11
CA2857046A1 (en) 2013-08-01
IL232777A0 (en) 2014-07-31
JP2020023513A (ja) 2020-02-13
HK1198921A1 (en) 2015-06-19
EP2806868A1 (en) 2014-12-03
KR20140117379A (ko) 2014-10-07
PH12014501693A1 (en) 2014-10-20
SG11201404088TA (en) 2014-10-30
JP2015504921A (ja) 2015-02-16
JP2018065818A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
JP2015504921A5 (cg-RX-API-DMAC7.html)
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
CN101573031B (zh) 抗微生物组合物
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
Boswell et al. Bactericidal properties of moxifloxacin and post-antibiotic effect
FI3006038T3 (fi) Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn
ATE455786T1 (de) 6-11 bicyclische ketolidderivate
Meije et al. Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection
AU2013211982A1 (en) Antimicrobial compositions comprising DGLA, 15-OHEPA and/or 15-HETrE and methods of use thereof
JP2012501349A5 (cg-RX-API-DMAC7.html)
WO2020028561A1 (en) Bismuth-thiol compositions and methods for treating wounds
GEAP202416514A (en) Chromane amidine monobactam antibiotics
ZA202309204B (en) Lactivicin compounds, their preparation and use as antibacterial agents
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
JP2018521143A5 (cg-RX-API-DMAC7.html)
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗mrsa活性医薬組成物
US20140038915A1 (en) Methods for treating bacterial infection
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
RU2018109421A (ru) Лизобактин для применения для лечения коровьего мастита
JP2016519109A5 (cg-RX-API-DMAC7.html)
WO2024019916A3 (en) Chromane amidine monobactam compounds for the treatment of bacterial infections
WO2025038882A3 (en) Method for treatment of seizures
ZA202502737B (en) Application of artemisia seeds in the preparation of medicament for treating salivation caused by oral scalds or gastric mucosal scalds in pigs
Mardani Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20160328